ACAD vs. BHC, ARWR, RARE, MRTX, IONS, ELAN, ROIV, INSM, LEGN, and ASND
Should you be buying ACADIA Pharmaceuticals stock or one of its competitors? The main competitors of ACADIA Pharmaceuticals include Bausch Health Companies (BHC), Arrowhead Pharmaceuticals (ARWR), Ultragenyx Pharmaceutical (RARE), Mirati Therapeutics (MRTX), Ionis Pharmaceuticals (IONS), Elanco Animal Health (ELAN), Roivant Sciences (ROIV), Insmed (INSM), Legend Biotech (LEGN), and Ascendis Pharma A/S (ASND). These companies are all part of the "pharmaceutical preparations" industry.
Bausch Health Companies (NYSE:BHC) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, media sentiment, valuation, earnings, community ranking and profitability.
Bausch Health Companies has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500. Comparatively, ACADIA Pharmaceuticals has a beta of 0.41, meaning that its share price is 59% less volatile than the S&P 500.
In the previous week, ACADIA Pharmaceuticals had 8 more articles in the media than Bausch Health Companies. MarketBeat recorded 8 mentions for ACADIA Pharmaceuticals and 0 mentions for Bausch Health Companies. ACADIA Pharmaceuticals' average media sentiment score of 1.93 beat Bausch Health Companies' score of 0.46 indicating that Bausch Health Companies is being referred to more favorably in the media.
ACADIA Pharmaceuticals has a net margin of -0.21% compared to ACADIA Pharmaceuticals' net margin of -5.07%. Bausch Health Companies' return on equity of -0.41% beat ACADIA Pharmaceuticals' return on equity.
ACADIA Pharmaceuticals has lower revenue, but higher earnings than Bausch Health Companies. ACADIA Pharmaceuticals is trading at a lower price-to-earnings ratio than Bausch Health Companies, indicating that it is currently the more affordable of the two stocks.
Bausch Health Companies currently has a consensus price target of $11.33, indicating a potential upside of 79.32%. ACADIA Pharmaceuticals has a consensus price target of $28.94, indicating a potential upside of 94.47%. Given Bausch Health Companies' stronger consensus rating and higher probable upside, analysts plainly believe ACADIA Pharmaceuticals is more favorable than Bausch Health Companies.
ACADIA Pharmaceuticals received 526 more outperform votes than Bausch Health Companies when rated by MarketBeat users. Likewise, 72.96% of users gave ACADIA Pharmaceuticals an outperform vote while only 61.90% of users gave Bausch Health Companies an outperform vote.
78.7% of Bausch Health Companies shares are held by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. 8.1% of Bausch Health Companies shares are held by insiders. Comparatively, 28.3% of ACADIA Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
ACADIA Pharmaceuticals beats Bausch Health Companies on 13 of the 18 factors compared between the two stocks.
Get ACADIA Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACAD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ACAD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ACADIA Pharmaceuticals Competitors List
Related Companies and Tools
